Goz B, Jeffs L
Department of Pharmacology, School of Medicine, University of North Carolina at Chapel Hill.
J Pharmacol Exp Ther. 1994 Aug;270(2):480-4.
In cultured cells, dipyridamole, in a dose-dependent manner, prevented the enhancement by 1-beta-D-arabinofuranosylcytosine (AraC) of either N-phosphonoacetyl-L-aspartate (PALA)- or methotrexate- resistance frequency. Maximal blockade of enhancement of PALA-resistance frequency occurred if the dipyridamole was added with or within about 20 hr of PALA addition. Thereafter, the effect of dipyridamole decreased. Nitrobenzylthioinosine similarly reduced AraC enhancement of PALA- and methotrexate-resistance frequency. Both dipyridamole and nitrobenzylthioinosine inhibited uridine and thymidine uptake into cells to a similar extent in cells pretreated or not with AraC. Thus, although inhibition of nucleoside uptake would seem a reasonable explanation for the effect on PALA-resistance frequency by dipyridamole, there is no obvious explanation at present of how dipyridamole selectively affects resistance frequency in AraC-pretreated cells.
在培养细胞中,双嘧达莫以剂量依赖方式,阻止了1-β-D-阿拉伯呋喃糖基胞嘧啶(AraC)对N-膦酰乙酰-L-天冬氨酸(PALA)或甲氨蝶呤耐药频率的增强作用。如果在添加PALA时或添加PALA后约20小时内添加双嘧达莫,PALA耐药频率增强作用的最大阻断就会出现。此后,双嘧达莫的作用减弱。硝基苄基硫代肌苷同样降低了AraC对PALA和甲氨蝶呤耐药频率的增强作用。在未用或已用AraC预处理的细胞中,双嘧达莫和硝基苄基硫代肌苷对尿苷和胸苷摄入细胞的抑制程度相似。因此,虽然核苷摄入的抑制似乎是双嘧达莫对PALA耐药频率产生影响的一个合理的解释,但目前对于双嘧达莫如何选择性地影响AraC预处理细胞中的耐药频率,尚无明确的解释。